Disease
Areas of Focus
 Solid
Organ Transplant Rejection
On
any given day, more than 86,000 people in the United States
are waiting to receive a donor organ.1 Patients fortunate
to receive a transplanted organ still face a number of medical
challenges,
the biggest of which is usually organ rejection.
A
transplant recipient must be on a regimen of drugs designed to
prevent the
host immune system from rejecting the new organ. Unfortunately,
many anti-rejection drugs have significant cardiovascular and
renal toxicities. Thus, while these drugs decrease the risk of
rejection,
they sometimes contribute to long-term cardiovascular complications
by causing increases in blood pressure, elevations in cholesterol,
and development of diabetes as well as reduced kidney function.
Bristol-Myers
Squibb is currently testing an investigational compound that
may avoid or reduce some of the problems associated
with current
therapies.
Back
to Disease Areas
1.
HHS/HRSA/HSB/DOT. 2005 OPTN/SRTR Annual Report 1995-2004.
The data and analyses reported in the 2005 Annual Report of the
U.S. Organ Procurement and Transplantation Network and the Scientific
Registry of Transplant Recipients have been supplied by UNOS and
URREA under contract with HHS. The authors alone are responsible
for reporting and interpreting these data; the views expressed
herein are those of the authors and not necessarily those of the
U.S. Government. |
